Repotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion); Benefit assessment according to §35a SGB V

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen 2026 Open access

Read full text
Authors: Institute for Quality and Efficiency in Health Care
DOI: 10.60584/a25-58_en
Cited by: 0

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Sarcoma Diagnosis and Treatment Cancer Mechanisms and Therapy

Publication details

Journal / source
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Publication date
11 February 2026
Language
EN